Alltech's mycotoxin innovation has a proven scientific backbone that includes eight patents and 52 peer-reviewed papers. An additional 17 PhDs and 19 Master's have been completed through 14 years of research on the technology.
"The defense of Alltech's patent was simple because the company has complete confidence in the wealth of its research data and the exceptional characteristics of its technology. When it comes to mycotoxins, Alltech is unrivaled in the marketplace," said Mike Castle, chief legal officer at Alltech.
—From Alltech news release
